Clare Ozawa Net Worth

The estimated Net Worth of Clare Ozawa is at least $8.23 Milione dollars as of 18 October 2021. Clare Ozawa owns over 550,000 units of Oyster Point Pharma Inc stock worth over $55,705 and over the last 5 years he sold OYST stock worth over $8,162,000. In addition, he makes $7,333 as Independent Director at Oyster Point Pharma Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Clare Ozawa OYST stock SEC Form 4 insiders trading

Clare has made over 2 trades of the Oyster Point Pharma Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 550,000 units of OYST stock worth $8,162,000 on 18 October 2021.

The largest trade he's ever made was buying 562,500 units of Oyster Point Pharma Inc stock on 4 November 2019 worth over $9,000,000. On average, Clare trades about 101,136 units every 65 days since 2019. As of 18 October 2021 he still owns at least 4,987 units of Oyster Point Pharma Inc stock.

You can see the complete history of Clare Ozawa stock trades at the bottom of the page.

Clare Ozawa biography

Dr. Clare R. Ozawa Ph.D. serves as Independent Director of the Company. Dr. Ozawa has served as a Managing Director at Versant Venture Management LLC, a life science venture capital firm investing in early stage healthcare companies, since July 2017 and was an investment professional at Versant from 2008 to 2011. Prior to re-joining Versant, Dr. Ozawa was the Chief Business Officer of Inception Sciences from January 2011 to May 2014 and served as Inception’s Chief Operating Officer from June 2014 to July 2017. She also worked in the Office of the Chief Executive Officer at Novartis Pharma from 2006 to 2008 and at McKinsey & Company from 2002 to 2006. Dr. Ozawa received a B.S. in biological sciences and a Ph.D. in neurosciences from Stanford University. Ozawa is qualified to serve on our board of directors because of her expertise and experience in the life sciences, including her educational background, and her management experience.

What is the salary of Clare Ozawa?

As the Independent Director of Oyster Point Pharma Inc, the total compensation of Clare Ozawa at Oyster Point Pharma Inc is $7,333. There are 11 executives at Oyster Point Pharma Inc getting paid more, with Jeffrey Nau having the highest compensation of $4,037,700.

What's Clare Ozawa's mailing address?

Clare's mailing address filed with the SEC is C/O OYSTER POINT PHARMA, INC., 202 CARNEGIE CENTER, SUITE 106, PRINCETON, NJ, 08540.

Insiders trading at Oyster Point Pharma Inc

Over the last 5 years, insiders at Oyster Point Pharma Inc have traded over $24,486,000 worth of Oyster Point Pharma Inc stock and bought 3,552,871 units worth $59,028,668 . The most active insiders traders include Ali Behbahani, Venture Capital Vi, L.P.Ver... e Clare Ozawa. On average, Oyster Point Pharma Inc executives and independent directors trade stock every 27 days with the average trade being worth of $2,204,444. The most recent stock trade was executed by Daniel Lochner on 1 November 2021, trading 8,590 units of OYST stock currently worth $98,871.

What does Oyster Point Pharma Inc do?

Oyster Point Pharma is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases. Oyster Point Pharma's lead product candidate, OC-01 (varenicline) nasal spray, a highly selective cholinergic agonist, is being developed as a nasal spray to treat the signs and symptoms of dry eye disease. In pre-clinical and clinical studies, OC-01 (varenicline) nasal spray was shown to have a novel mechanism of action via activation of the trigeminal parasympathetic pathway to stimulate the glands and cells responsible for natural tear film production, known as the lacrimal functional unit.

Complete history of Clare Ozawa stock trades at Oyster Point Pharma Inc

Oyster Point Pharma Inc executives and stock owners

Oyster Point Pharma Inc executives and other stock owners filed with the SEC include:

• Jeffrey Nau,
  President, Chief Executive Officer, Director
• John Snisarenko,
  Chief Commercial Officer
• Daniel Lochner,
  Chief Financial Officer
• Dr. Jeffrey Nau Ph.D., MMS,
  Pres, CEO & Director
• Daniel Lochner M.B.A.,
  Chief Financial Officer
• John Snisarenko M.B.A.,
  Chief Commercial Officer
• Mark Murray,
  Director
• Ali Behbahani,
  Chairman of the Board
• Benjamin Tsai,
  Independent Director
• Aimee Weisner,
  Independent Director
• William Link,
  Independent Director
• Clare Ozawa,
  Independent Director
• Tim McCarthy,
  IR Contact Officer
• Michael Atieh,
  Director
• Dr. Marian Macsai M.D.,
  Chief Medical Officer of Medical Affairs
• Loni Da Silva M.S.,
  Sr. VP of Regulatory Affairs
• Raegan A. McClain CCEP, J.D., L.L.M.,
  Chief Compliance Officer
• Barry Rosenfeld J.D.,
  Sr. VP & Gen. Counsel
• Dr. Eric Carlson Ph.D.,
  Chief Scientific Officer
• George Donato M.B.A.,
  Sr. VP of CMC & Operations
• Ventures, Llc Vida,
  10% owner
• Point Pharma I, Llc Oyster,
  10% owner
• Vision Llckkr Healthcare St...,
  
• Gp Iv, L.L.C.Inv Opps Iv, L...,
  
• Michael Ackermann,
  Director
• Perkins Caufield & Byers Xi...,
  
• Venture Capital Vi, L.P.Ver...,
  
• Fund Holdings L.P.Kravis He...,
  
• George Christopher Eliades,
  Director
• Donald J Santel,
  Director
• Enterprise Associates 14, L...,